AstraZeneca PLC Revenue in 2025

AstraZeneca PLC reported $58.7B in revenue for fiscal year 2025. This represents a growth of 8.6% compared to the 2024 figure of $54.1B.

Farxiga was selected for the first round of Medicare price negotiations under the Inflation Reduction Act — and 2026 is also the year it loses market exclusivity. That double headwind on the company's cardiovascular drug, which generated billions annually, is the most consequential near-term financial risk on AstraZeneca's balance sheet. Revenue has compounded at roughly 28% per year from 2023 to 2025: $45.8 billion, $54.1 billion, $58.7 billion. Net income reached $10.2 billion in FY2025 on $58.7 billion in total revenue — a 17.4% net margin that is high for a company investing at this pace in clinical trials and commercial launches. The company completed 74 regulatory events and 24 pipeline progression events in 2024, metrics that directly determine executive compensation under the Global Executive Bonus Plan. The Alexion acquisition for $39 billion in 2021 added Soliris and Ultomiris to the portfolio — rare disease drugs with annual per-patient costs exceeding $500,000. Rare disease economics produce extraordinary unit margins but concentration risk: lose a single indication's patent protection and the revenue impact is immediate and severe because no volume competitor can soften the blow. Tezspire, the severe asthma drug developed in partnership with Amgen, achieved $371 million in combined quarterly sales in Q1 2025, up 81% year-over-year. AstraZeneca's share was $217 million in that quarter alone. Drugs reaching that growth rate in the respiratory category, which historically turns over slowly, suggest that Tezspire is finding patients beyond the most obvious clinical indication — a pattern that, if it continues, could make respiratory a third major growth franchise alongside oncology and rare disease.